Navigation Links
The California Healthcare Institute Responds to New Efforts to Repeal the Federal Medical Device Excise Tax
Date:2/7/2013

La Jolla, Calif. (PRWEB) February 07, 2013

The California Healthcare Institute (CHI) today released a statement in response to reintroduced legislation to repeal the 2.3 percent federal excise tax on medical device manufacturers.

“CHI strongly supports efforts to repeal the medical device excise tax, which threatens important research and development, and is already pressuring jobs at a time when we should be doing everything we can to encourage investment, innovation and job creation,” said CHI President and CEO David L. Gollaher, Ph.D. “As a tax on revenues, not profits, it especially discriminates against smaller device companies with pioneering ideas that have yet to reach the marketplace.”

Given the size and scope of the medical technology sector’s presence in California, the 2.3 percent tax has a disproportionate impact on the state. California is home to more than 1,200 medical technology companies — more than any other state in the nation — and the nearly 72,000 medical device jobs in California represent roughly 17 percent of the total U.S. medical technology workforce. Vibrant medical technology clusters exist in and around San Diego, San Francisco/Silicon Valley, Orange County and Sacramento, as well as the Los Angeles, Ventura/Santa Barbara, and Riverside/San Bernardino regions.

In California and nationwide, the tax has already had a negative effect on industry innovators, with large and small companies looking for ways to cut costs, which generally means hiring fewer workers and reducing investments in R&D.

CHI continues to work with California’s congressional representatives, including many who have signed on to co-sponsor the measure, in order to repeal this destructive tax. CHI applauds the bill’s original co-sponsors: John Campbell (R-Irvine), Susan Davis (D-San Diego), Jeff Denham (R-Turlock), Darrell Issa (R-Vista), Doug LaMalfa (R-Richvale), Scott Peters (D-San Diego), Ed Royce (R-Fullerton), David Valadao (R-Hanford) and Juan Vargas (D-San Diego).

About CHI
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is http://www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10409904.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members
2. Precision Coating to Showcase Next Generation Coating Deposition Technology at MD&M West Show in Anaheim, California
3. California Biomedical Companies Report Higher Product Approvals, Fewer Delays
4. Bayer CropScience Announces Registration for use of Alion on Grapes in California
5. New "GMO Inside" Campaign Denounces Corporate Disinformation Campaign That Defeated Californias Prop 37
6. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
7. University of California, San Francisco (UCSF) Selects Conflict of Interest Management System
8. California Physical Therapists Prediction Proved "Right" by Results of State Board Audit
9. California Healthcare Institute Issues Statement on Supreme Court Ruling on the Affordable Care Act
10. Californians Take One Step Closer to Directly Accessing Physical Therapy Services for Immediate Treatment
11. Lightning Brewery’s Craft Beer Old Tempestuous Ale Wins Best of Show at 2012 California State Fair Commercial Brewing Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... FireflySci, Inc ... Founded in late 2014, FireflySci had the goal of bringing their powerful cuvette ... continues to shape the path that FireflySci is going on as they add yet ...
(Date:2/23/2017)... SAN RAFAEL, Calif., Feb. 23, 2017 ... of U.S. dollars, except per share data, unaudited)Three Months ... ChangeTotal BioMarin Revenue $ ...     22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... Capitol Hill neighborhood, with its swanky shops, parks and cafés, might ... salon to set up shop. But there,s Hair Fairies ... on E Madison Ave, and CEO Maria Botham ... we pride ourselves on being a destination for parents and ... associated with lice. Everyone can get lice – it doesn,t ...
Breaking Biology Technology:
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
Breaking Biology News(10 mins):